These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8137583)

  • 1. Intraperitoneal distribution imaging prior to chromic phosphate (P-32) therapy in ovarian cancer patients.
    Tulchinsky M; Eggli DF
    Clin Nucl Med; 1994 Jan; 19(1):43-8. PubMed ID: 8137583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pleuroperitoneal migration of intraperitoneal phosphorus-32-chromic phosphate therapy for stage I ovarian carcinoma.
    Wilkinson RH
    J Nucl Med; 1996 Apr; 37(4):636-9. PubMed ID: 8691256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peritoneoscintigraphy in detection of improper placement of peritoneal catheter into bowel lumen prior to chromic phosphate P-32 therapy. A case report.
    Neutze J; Van Nostrand D; Major W
    Clin Nucl Med; 1985 Nov; 10(11):777-9. PubMed ID: 4075668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Observations on the intraperitoneal distribution of chromic phosphate (32P) suspension for intraperitoneal therapy.
    Sullivan DC; Harris CC; Currie JL; Wilkinson RH; Creasman WT
    Radiology; 1983 Feb; 146(2):539-41. PubMed ID: 6849103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on the role of radiotherapy in ovarian cancer.
    Lanciano R; Reddy S; Corn B; Randall M
    Semin Oncol; 1998 Jun; 25(3):361-71. PubMed ID: 9633849
    [No Abstract]   [Full Text] [Related]  

  • 6. Intraperitoneal radioactive chromic phosphate P 32 in the treatment of ovarian cancer.
    Powell JL; Burrell MO; Kirchner AB
    South Med J; 1987 Dec; 80(12):1513-7. PubMed ID: 3423895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant intraperitoneal chromic phosphate therapy in a woman with early ovarian carcinoma and pelvic infection with resulting catastrophic complications.
    McGowan L
    Clin Nucl Med; 1994 Aug; 19(8):696-8. PubMed ID: 7955749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraperitoneal radioactive chromic phosphate (P32) in the treatment of ovarian cancer.
    Powell JL; Kirchner AB
    J Med Assoc Ga; 1984 Jan; 73(1):21-5. PubMed ID: 6707541
    [No Abstract]   [Full Text] [Related]  

  • 9. Intraperitoneal chromic phosphate in ovarian cancer: risks and benefits.
    Potter ME; Partridge EE; Shingleton HM; Soong SJ; Kim RY; Hatch KD; Austin JM
    Gynecol Oncol; 1989 Mar; 32(3):314-8. PubMed ID: 2920951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group.
    Varia MA; Stehman FB; Bundy BN; Benda JA; Clarke-Pearson DL; Alvarez RD; Long HJ;
    J Clin Oncol; 2003 Aug; 21(15):2849-55. PubMed ID: 12885800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphorus-32-chromic phosphate for ovarian cancer: I. Fractionated low-dose intraperitoneal treatments in conjunction with platinum analog chemotherapy.
    Pattillo RA; Collier BD; Abdel-Dayem H; Ozker K; Wilson C; Ruckert AC; Hamilton K
    J Nucl Med; 1995 Jan; 36(1):29-36. PubMed ID: 7799078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant intraperitoneal chromic phosphate therapy for women with apparent early ovarian carcinoma who have not undergone comprehensive surgical staging.
    Soper JT; Berchuck A; Clarke-Pearson DL
    Cancer; 1991 Aug; 68(4):725-9. PubMed ID: 1855171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraperitoneal chromic phosphate therapy after second-look laparotomy for ovarian cancer.
    Varia M; Rosenman J; Venkatraman S; Askin F; Fowler W; Walton L; Halle J; Currie J
    Cancer; 1988 Mar; 61(5):919-27. PubMed ID: 3338057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromic phosphate therapy in carcinoma of the ovary.
    Goodman A; Bornstein L; Ball H; Smith DM; Bankoff M
    J Am Coll Surg; 1994 Oct; 179(4):401-6. PubMed ID: 7921388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of scintigraphic and contrast peritoneography in gynecologic malignancies.
    Yoonessi M; Abdel-Dayem HM; Shalaby OF
    Diagn Gynecol Obstet; 1982; 4(1):75-8. PubMed ID: 7075451
    [No Abstract]   [Full Text] [Related]  

  • 16. Intraperitoneal chromic phosphate P 32 as salvage therapy for persistent carcinoma of the ovary after surgical restaging.
    Soper JT; Wilkinson RH; Bandy LC; Clarke-Pearson DL; Creasman WT
    Am J Obstet Gynecol; 1987 May; 156(5):1153-8. PubMed ID: 3578429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five and ten year estimated survival and disease-free rates after intraperitoneal chromic phosphate; stage I ovarian adenocarcinoma.
    Piver MS; Lele SB; Bakshi S; Parthasarathy KL; Emrich LJ
    Am J Clin Oncol; 1988 Oct; 11(5):515-9. PubMed ID: 3177251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Letter: Loculation as a contraindication to intracavitary 32P-chromic phosphate therapy.
    Vider M; Deland FH; Maruyama Y
    J Nucl Med; 1976 Feb; 17(02):150-1. PubMed ID: 1245879
    [No Abstract]   [Full Text] [Related]  

  • 19. Therapeutic intraperitoneal 32P: a clinical assessment of the dynamics of distribution.
    Kaplan WD; Zimmerman RE; Bloomer WD; Knapp RC; Adelstein SJ
    Radiology; 1981 Mar; 138(3):683-8. PubMed ID: 7465847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unintentional intraluminal small bowel catheter placement detected by Tc-99m SC scan obtained before planned intraperitoneal phosphorus-32 therapy.
    Gritters LS; Lelle R; Morley GW; Wahl RL
    Clin Nucl Med; 1993 Mar; 18(3):249-50. PubMed ID: 8462222
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.